Kiadis Hosts NYC Meeting to Discuss Candidate Therapy ATIR101, Risks of Haploidentical HSCT in Blood Cancer
News
Kiadis Pharma hosted a May 31 lunch meeting in New York to analyze the risks and benefits of haploidentical hematopoietic stem cell transplants (HSCT) in treating blood cancers. Two experts, Dr. Stephen ... Read more